Evidence map›Paper›PMID 37905661›Full record

ArticleIn vivo (Athens, Greece)

The Clinical Impact of the Pretreatment Platelet-to-Lymphocyte Ratio in Gastric Cancer Patients Who Receive Curative Treatment.

Toru Aoyama, Itaru Hashimoto, Yukio Maezawa, Kentaro Hara, Keisuke Kazama, Masakatsu Numata, Natsumi Kamiya, Hiroshi Tamagawa, Sho Sawazaki, Shinnosuke Kawahara and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Toru Aoyama *Department of Surgery, Yokohama City University, Yokohama, Japan; t-aoyama@lilac.plala.or.jp.
Itaru Hashimoto *Department of Surgery, Yokohama City University, Yokohama, Japan.
Yukio MaezawaDepartment of Surgery, Yokohama City University, Yokohama, Japan; ykzawa0@gmail.com.
Kentaro HaraDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Keisuke KazamaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Masakatsu NumataDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Natsumi KamiyaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Hiroshi TamagawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Sho SawazakiDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Shinnosuke KawaharaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Keisuke KomoriDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Ayako TamagawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Haruhiko ChoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Junya MoritaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Kazuki OtaniDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Aya KatoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Mie TanabeDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Takashi OshimaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Norio YukawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Aya SaitoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Yasushi RinoDepartment of Surgery, Yokohama City University, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe platelet-to-lymphocyte ratio (PLR) is a promising prognostic marker in some malignancies. The present study evaluated the clinical impact of the PLR in patients with gastric cancer who underwent curative resection. PATIENTS AND

methodsThis study included 258 patients who underwent curative treatment for gastric cancer between 2005 and 2020. The prognosis and clinicopathological parameters between the high- and low-PLR statuses were analyzed.

resultsThe overall survival (OS) stratified by each clinical factor was compared using the log-rank test, and a significant difference was observed using a pretreatment PLR of 150. When comparing the patient backgrounds between the high-PLR (PLR≥150) and low-PLR (PLR<150) groups, there were no significant differences between the two groups. The OS rates at 3 and 5 years after surgery were significantly higher at 70.8% and 60.4%, respectively, for the high-PLR group than at 83.6% and 79.7%, respectively, for the low-PLR group. Univariate and multivariate analyses of the OS showed that the PLR was a significant prognostic factor. In addition, when comparing the first recurrence sites, there were significant differences in peritoneal recurrence.

conclusionThe PLR is a significant risk factor for gastric cancer, making it a promising prognostic factor for patients with gastric cancer.

Indexed as

Stomach NeoplasmsBlood PlateletsHumansLymphocytesPrognosisRetrospective Studiesgastric cancerlymphocytePlateletsurvival

Identifiers

PMID37905661
PMCPMC10621422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.